tbuckley/cabot-search huggingface dataset:
THU0555 10 YEAR PROGNOSIS OF PATIENTS DIAGNOSED WITH FAMILIAL MEDITERRANEAN FEVER
Authors: Bugra Han Egeli, Asli Ece Soykut, Bilgesu Ergezen, Serdal Ugurlu
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> In Familial Mediterranean Fever (FMF), other than amyloidosis factors affecting mortality are being debated. In our previous study, we did not observe any atherosclerotic plaque formation in carotid or femoral artery. We thought that the risk of atherosclerosis did not increase in patients diagnosed with FMF. <h3>Objectives:</h3> The aim of this study was to assess the 10 year prognosis and comorbidity of patients diagnosed with FMF who have been treated in our rheumatology clinic. <h3>Methods:</h3> The sample group is a subset of 2009 study. In 2009, the patients who already had myocardial infarction or cancer diagnosis were excluded. The patients were interviewed with polar questions of whether they were diagnosed with acute myocardial infarction (AMI), cerebrovascular events, cancer, diabetes, and hypertension. <h3>Results:</h3> We studied 71 patients (37 males, 34 females; mean age: 49.66±6.91) with FMF, and 59 patients (24 males, 35 females) in healthy control (HC) group. The gender and age difference between two groups was not found significant. During 10 year follow-up, 8% of FMF patients had either a cardiovascular or cerebrovascular event comparing to 5% in HC (p&gt;0.05). 3% of FMF patients had a cancer diagnosis comparing to 3% in HC (p&gt;0.05). Even though diabetes mellitus diagnosis rate was higher in FMF patients (15% to 10%), results were still not significant (p&gt;0.05). Hypertension diagnosis was 5% higher in FMF group (p&lt;0.05) <h3>Conclusion:</h3> Even though there was a significant increase in hypertension, increased diabetes, cancer, and AMI/Stroke ratio was not found significant when compared to the HCs. Therefore, any cardiovascular and malignancy related comorbidities are not associated with FMF. <h3>References:</h3> [1] Ugurlu S, Seyahi E, Cetinkaya F, Ozbakir F, Balci H, Ozdogan H. Intima media thickening in patients with familial Mediterranean fever. Rheumatology (Oxford). 2009Aug;48(8):911-5. <h3>Disclosure of Interests:</h3> None declared
AB0434 EARLY EXPERIENCE WITH JAK INHIBITOR PRESCRIBING IN THE UK: RESULTS FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER FOR RHEUMATOID ARTHRITIS (BSRBR-RA)
Authors: Jennifer Page, Lianne Kearsley-Fleet, Rebecca Davies, Kath Watson, Kimme Hyrich, Mark Lunt
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> In 2017 a new class of oral disease modifying anti-rheumatic drugs (DMARDs), janus kinase inhibitors (JAKi), were licensed for rheumatoid arthritis (RA): baricitinib and tofacitinib. In the UK, they are approved for use in patients with high disease activity with or without methotrexate, following failure of conventional synthetic (cs) DMARDs or biologic DMARDs, the latter when rituximab is contraindicated. As a new therapy option, it is currently unclear how and when these drugs are being prescribed in patients with RA. <h3>Objectives:</h3> This analysis aims to describe the characteristics of patients starting JAKi and registered with the BSRBR-RA. <h3>Methods:</h3> The BSRBR-RA aims to capture exposure and outcome data in patients with RA receiving biologics, biosimilars and targeted synthetic DMARDs. At the start of therapy, demographic and clinical data, including past treatment data, are collected. Characteristics of all patients receiving a JAKi for the first time with data recorded in the BSRBR-RA up to 30/11/2018 are described. <h3>Results:</h3> To 30/11/2018, 443 patients in the BSRBR-RA have been treated with a JAKi; 374 patients baricitinib and 69 tofacitinib (Table). Twenty-eight percent of baricitinib and 13% of tofacitinib patients received a JAKi following csDMARDs, with no prior biologic exposure. Of these, 15% had a prior malignancy history. Of those with prior exposure, the median number of previous biologics was 3 (IQR 2-4) and 52% had received rituximab. Forty-three percent were receiving concurrent methotrexate. <h3>Conclusion:</h3> To date, more patients have been recruited starting baricitinib than tofacitinib, likely owing to the later licensing of tofacitinib. Two groups are emerging with a quarter of patients receiving JAKi immediately after csDMARDs and a majority as a later stage alternative following multiple biologics. Further recruitment and follow-up patients will allow for analysis of real-world safety and effectiveness, but differences in patient characteristics will need to be considered in any comparative effectiveness analyses. <h3>Disclosure of Interests:</h3> Jennifer Page: None declared, Lianne Kearsley-Fleet: None declared, Rebecca Davies: None declared, Kath Watson: None declared, Kimme Hyrich Grant/research support from: Grants to institution: BMS, Pfizer, UCB, Mark Lunt: None declared
Never-smoking women with lung cancer from the Spanish WORLD07 database.
Authors: Dolores Isla, Mariano Provencio, Margarita Majem, Enriqueta Felip, Nuria Vinolas, Rosario Garcia Campelo, Ramon de las Penas, Enric Carcereny, Vicente Alberola, Manuel Domine, Remei Blanco, Javier Dorta, Reyes Bernabé, Carmen Guillen, Catalina Vadell, Inmaculada Maestu, Delvys Rodriguez, Belen Rubio-Viqueira, Salvador Figueroa, Pilar Garrido López
Journal: Journal of Clinical Oncology (2012)

1531 Background: Gender differences in lung cancer (LC) have been reported, but with many unresolved issues yet. Tobacco causes the majority of women lung cancer (WLC), although the rate of never-smoking WLC is higher than in men. Several factors may play etiologic roles, and an in-depth understanding is needed. Methods: WORLD07 is a Spanish prospective, multicenter, epidemiologic female-specific LC database sponsored by ICAPEM, a professional association committed with WLC research. In order to improve the knowledge on never-smoking WLC, information has been extracted from WORLD07 database. Results: From October/2007 to October/2011, 1371 newly diagnosed WLC were included in an e-database from 32 centers, 539 (39.3%) never-smoking. Patient (p) characteristics: median age 71.1 years(y); median age of menarche 13y.; motherhood 91.2% (median 2.3 children, median age at first child 26.4y); oral contraceptive use 11.9%; postmenopausal 88.9% (median age of menopause 49y); HRT 5.2%; second-hand smokers 40% (work-exposure 17.1%, home-exposure 88.8%); obesity 16.3%; familiar history of cancer 39.9% (LC 29.8%); previous history of cancer 13% (breast/lung/cervix: 41.4/5.7/2.9%); current LC histology(%): adenocarcinoma/SqCC/LCC/SCLC: 83.4/6.2/5.5/3.9; EGFR mut+ (268 p analyzed): 55.5% (exon 19/20/21(%): 61.1/7.4/36.9); TNM NSCLC I/II/III/IV(%): 14/3.3/19.8/60.3. Treatment: EGFR-TKI in p EGFR mut+, stage IV(1 st -/2 nd -line)(%): 51.7/15.4; stage IV NSCLC (1 st -line/2 nd -line): platinum-based CT 42.5%, EGFR-TKI 33.5%, combinations with bevacizumab 2.9% / EGFR-TKI 15.8%. Overall survival: median 27 months(m), 1/2-y(%) 74.8/55.2; stage IV NSCLC: median 20.5m, 1/2-y(%) 67/46; EGFR-mut+ p: median 27.3m, 1/2-y(%) 75/54.3. Conclusions: According to our e-database, WLC showed high rates of never-smokers (39.3%), and of relatives diagnosed with malignant tumours (39.9%, ≅1/3 LC). Adenocarcinoma was the most frequent histology (76.1%), and more than half of the cases analyzed harboured EGFR mutations. Although 40% were second-hand smokers, further investigations are warranted. Survival outcomes remain satisfactory, as expected from this selected subgroup of p. Additional epidemiologic and treatment data will be presented.
PB2000 OUTCOME OF PEDIATRIC NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA, IS ABVD THE BEST REGIMEN? 10 YEARS SINGLE CENTER EXPERIENCE, REPORT FROM CHILDREN CANCER HOSPITAL, EGYPT.
Authors: Y. Madney, A. abdallha, S. Ahmed, M. romeih, S. fikry, M. zaghloul, H. taha, E. Mohammed, I. attia
Journal: HemaSphere (2019)

Background: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an uncommon subtype of Hodgkin lymphoma (HL) in children and accounts for 5–10% of all pediatric HL. Aims: The aim of the study to analyze the clinical characteristics and treatment outcome of Pediatric NLPHL. Methods: Retrospective study including all newly diagnosed patients less than 18 years old with NLPHL and treated in children cancer hospital Egypt CCHE between 2007 and 2017. Results: Among 43 pediatric NLPHL patients, 29 had early stage (18 with stage I, 11 with stage II). Fourteen patients had advanced stage (7 with stage III &amp; 7 with stage IV). Eleven patients had a mediastinal disease, 8 patients had splenic involvement, 2 patient had bulky disease and 10 patient had B symptoms at diagnosis. 28 Patients with Early‐stage disease treatment; surgery and observation 6 patients, Chemotherapy 6 patients and Combined modality 17 patients. Relapse was seen in 7(25%) patients, 1 observation arm, 3 from chemotherapy arm (ABVD) and 3 from the combined arm (ABVD+IFRTH). 14 advanced stage patients received treatment; Chemotherapy (ABVD) 6 patients, Combined (ABVD+IFRTH) 8 patients, Relapse in 7 (50%) patients (all stage 4 disease), 6 from chemotherapy arm and 1 from the combined arm. 2 patients died (stage IV) from progressive disease and sepsis. B symptoms, mediastinal and splenic involvement had a significant impact on DFS on univariate analysis while combined treatment modality (Chemotherapy and Radiotherapy) had an impact on the outcome of both univariate and multivariate analysis. 5 Years DFS, OS for whole group was 64% and 94% respectively, while 5y DFS for early stage 83% and advanced stage 45% (p‐value = .01) and 5 Years OS for early stage was 100% and advanced stage 87 % (p‐value = .08). Summary/Conclusion: Early stage NLPHL had a better outcome but unexpected higher relapse in chemotherapy treatment arm raising a question about the role of radiotherapy while advanced stage disease had poor outcome rising a question of what should be the best chemotherapy regimen for pediatric NLPHL patients.
CDX-1140, a Novel Agonist CD40 Antibody with Potent Anti-Lymphoma Activity
Authors: Li-Zhen He, James Testa, Wasiuk Anna, Weidlick Jeffery, Crystal Sisson, Laura A. Vitale, Thomas O'Neill, Andrea Crocker, Jenifer Widger, Joel Goldstein, Henry C. Marsh Jr., Tibor Keler
Journal: Blood (2016)
Abstract 19195: Remote Ischemic Preconditioning Fails to Reduce Infarct Size in Type-2 Diabetes: Role of Defective Humoral Communication
Authors: Joseph Wider, Vishnu V Undyala, Peter Whittaker, Karin Przyklenk
Journal: Circulation (2017)

Remote ischemic preconditioning (RIPC: the phenomenon whereby brief episodes of ischemia in a distant organ render the heart resistant to infarction): 1) has been extensively documented in healthy ...
Incidence of Early Adverse Events in Primary Myelofibrosis (PMI). a Prospective Analysis from the Gruppo Laziale of Ph-Negative MPN
Authors: Ambra Di Veroli, Elena Rossi, Massimo Breccia, Marianna De Muro, Nicoletta Villivà, Malgorzata Monika Trawinska, Sabrina Crescenzi Leonetti, Guido Montanaro, Atelda Romano, Luca Petriccione, Ada D'Addosio, Antonia Centra, Annamaria Rauco, Barbara Anaclerico, Elisabetta Abruzzese, Luca Maurillo, Ida Carmosino, Marco Montanaro, Alessandro Andriani, Valerio De Stefano, Robin Foa, Roberto Latagliata
Journal: Blood (2017)
CD45RA+CCR7− CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab
Authors: Andre Kunert, Edwin A. Basak, Daan P. Hurkmans, Hayri E. Balcioglu, Yarne Klaver, Mandy van Brakel, Astrid A. M. Oostvogels, Cor H. J. Lamers, Sander Bins, Stijn L. W. Koolen, Astrid A. M. van der Veldt, Stefan Sleijfer, Ron H. J. Mathijssen, Joachim G. J. V. Aerts, Reno Debets
Journal: Journal for ImmunoTherapy of Cancer (2019)

Checkpoint inhibitors have become standard care of treatment for non-small cell lung cancer (NSCLC), yet only a limited fraction of patients experiences durable clinical benefit, highlighting the need for markers to stratify patient populations.
PB1870 IBRUTINIB PLUS VENETOCLAX SYNERGISTICALLY REDUCES SIGNALING AND VIABILITY IN CLL: IMPLICATIONS FOR BIOMARKER DISCOVERY
Authors: S.S. Skånland, A. Cremaschi, H. Bendiksen, J.U. Hermansen, D.B.T.G. Raj, L.A. Munthe, G.E. Tjønnfjord, K. Taskén
Journal: HemaSphere (2019)

Background: Recently, several small molecule drugs have been approved for the treatment of chronic lymphocytic leukemia (CLL). These drugs have significantly improved the management of this patient group. However, knowledge about how to combine the novel therapies for optimal effects and what patients will best benefit from them is still lacking. Aims: The aims of this study were to investigate whether drug synergies can be identified by single cell signaling analyses, and to identify potential signaling biomarkers for response to therapy. Methods: We investigated the effects of idelalisib, ibrutinib and venetoclax on 35 protein epitopes by phospho flow cytometry in CLL patient samples. Cell viability was monitored with internal markers for apoptosis in the phospho flow assays and with independent drug sensitivity screens. Results: The activity of proteins in the B cell receptor signalosome and the phosphatidylinositol 3‐kinase pathway were altered upon drug exposure. Combined treatment with ibrutinib and venetoclax give promising results in clinical studies and we show that this combination exerted synergistic inhibitory effects both on cell signaling (Figure 1a) and on cell viability (Figure 1a, b). Our analyses indicate that the standard dosages of ibrutinib and venetoclax can be lowered without loss of efficacy, potentially reducing drug costs and toxicities. Observed correlation between cell signaling and cell viability indicates that signaling molecules could serve as biomarkers to predict response to therapy. Summary/Conclusion: We suggest that phospho flow should be considered as a novel approach for dose and synergy prediction in a precision medicine setting for CLL. image
Extracellular Vesicle-Contained eNAMPT Delays Aging and Extends Lifespan in Mice
Authors: Mitsukuni Yoshida, Akiko Satoh, Jonathan B. Lin, Kathryn F. Mills, Yo Sasaki, Nicholas Rensing, Michael Wong, Rajendra S. Apte, Shin-ichiro Imai
Journal: Cell Metabolism (2019)
PB2312 PANORAMA OF HEMOGLOBINOPATHIES IN THE ANNABA REGION OF ALGERIA
Authors: A. Djenouni, F. GRIFI
Journal: HemaSphere (2019)

Background: Various national studies and some multicenter studies have been conducted in the past, highlighting the different foci of hemoglobinopathies. The North‐East of the country, essentially the border area with Tunisia, is an endemic area of sickle cell disease, posing many public health problems. Aims: The objectives of our work are: Census of hemoglobinopathies supported at our level Determine their epidemiological and evolutionary characteristics Methods: This is a retrospective study, extending from January 1988 to December 2017. A regular monitoring is carried out at varying rates depending on the type of hemoglobinopathy with annual impact assessments. Results: during this period a total of 1709 cases of hemoglobinopathies, was followed and each type its epidemiological characteristics: Major sickle cell syndromes: 1550 cases (90.7%) Homozygous form: 960 cases (61.94%) Double heterozygosity S / C: 99 cases (6.4%) Double heterozygosity S / B Thalassemia: 491 cases (31.68%) Epidemiological data: the current average age: 30.3 years [1 ‐ 69 years], the Sex ratio: 0.84, the majority of our patients come from Algerian‐Tunisian border area (79%). Inbreeding is present in 35.35% of cases, 70% of patients had at least one similar case in siblings. Hemoglobin C: 70 cases (4.1%) Epidemiological data: the current average age: 36 years [11 ‐ 69 years]; the Sex ratio: 0.70. Inbreeding is present in 59.69% of cases, 63% of patients had at least one similar case in siblings. The β Thalasemia: 89 cases (5.2%) Major form: 68 cases (76.4%) Intermediate form: 21 cases (23.6%) The epidemiological characteristics: the current average age: 19 years [03 ‐31 years], Sex ratio: 1.04. Inbreeding is present in 51% of cases and is 1st degree in 33.33%. Summary/Conclusion: Hemoglobin abnormalities are common in our region, mainly major sickle cell syndromes, posing a major health problem. Many efforts must be made at different levels to reduce the frequency of these abnormalities in this region and to provide adequate and above all multidisciplinary care for these patients.
Hypertrophic Cardiomyopathy—Need for Gene-Specific Treatment?—Reply
Authors: Caroline J. Coats, Michael P. Frenneaux, Perry M. Elliott
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Gemcitabine and oxaliplatin (GEMOX) alone or in combination with cetuximab as first-line treatment for advanced biliary cancer: Final analysis of a randomized phase II trial (BINGO).
Authors: David Malka, Laetitia Fartoux, Vanessa Rousseau, Tanja Trarbach, Eveline Boucher, Christelle De La Fouchardiere, Sandrine J. Faivre, Frédéric Viret, Jean-Frédéric Blanc, Eric Assenat, Pascal Hammel, Christophe Louvet, Goetz von Wichert, Michel Ducreux, Olivier Rosmorduc, Jean-Pierre Pignon, Tim F Greten
Journal: Journal of Clinical Oncology (2012)

4032 Background: Gemcitabine-platinum chemotherapy (CTx) regimens are widely accepted as first-line standard of care for patients (pts) with advanced biliary cancers (ABC). EGFR overexpression has been observed in ABC, suggesting that the combination with anti-EGFR monoclonal antibodies may be appropriate. Methods: Patients with ABC, WHO performance status (PS) 0-1, and without prior palliative CTx were eligible for this international, open-label, two-stage, non-comparative, randomized phase II trial. Patients received GEMOX (gemcitabine, 1 g/m² [10 mg/m²/min] at day [D]1 + oxaliplatin, 100 mg/m² at D2, arm A) or GEMOX + cetuximab (500 mg/m² at D1 or 2, arm B), every 2 weeks. The primary endpoint was crude 4-month progression-free survival (PFS) rate (H0, &lt;40%; H1, ≥60%; planned sample size, 100 pts, increased to 150 pts by amendment to allow subgroup analyses). Secondary endpoints were objective response rate (ORR), disease control rate (DCR), PFS, overall survival (OS), and toxicity (NCI-CTC v3.0). Exploratory endpoints included early metabolic response as assessed by PET at 1 month, and tumor KRAS mutational analysis. Results: From Oct. 2007 to Dec. 2009, we enrolled 150 pts (median age, 62 years; male, 57%; metastatic, 79%; cholangiocarcinoma, 84%; median follow-up, 30 months) (Table). Conclusions: GEMOX-cetuximab regimen was well tolerated and met its primary endpoint (4-month PFS ≥60%). However, median PFS and OS were similar in both arms. Exploratory analyses (e.g., KRAS tumor status) are underway to identify pt subgroups deriving benefit from the addition of cetuximab to CTx. [Table: see text]
SuperTranscripts: a data driven reference for analysis and visualisation of transcriptomes
Authors: Nadia M. Davidson, Anthony D. K. Hawkins, Alicia Oshlack
Journal: Genome biology (2017)

Numerous methods have been developed to analyse RNA sequencing (RNA-seq) data, but most rely on the availability of a reference genome, making them unsuitable for non-model organisms. Here we present superTranscripts, a substitute for a reference genome, where each gene with multiple transcripts is represented by a single sequence. The Lace software is provided to construct superTranscripts from any set of transcripts, including de novo assemblies. We demonstrate how superTranscripts enable visualisation, variant detection and differential isoform detection in non-model organisms. We further use Lace to combine reference and assembled transcriptomes for chicken and recover hundreds of gaps in the reference genome.
SAT0418 ASSOCIATION BETWEEN ANEMIA AND HYPERURICEMIA: KOREAN NATIONAL HEALTH AND NUTRITION SURVEY 2016
Authors: Yeonghee Eun, Eun-Jung Park, Ji-Young Chai, Hoon-Suk Cha, Eun-MI Koh, Hyungjin Kim, Jaejoon Lee
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Hyperuricemia and anemia may be related in terms of sharing comorbidities such as chronic kidney disease and cardiovascular disease. However, to our knowledge, no studies have been conducted on the relationship between two conditions. For the association of gout and anemia, there was a previous cohort study showing that patients with anemia had a 2-fold higher risk of gout compared to patients without anemia. And the risk of gout was significantly higher after adjusting for serum urate levels and kidney function. However, there is a lack of data on the relationship between anemia and hyperuricemia. <h3>Objectives:</h3> The purpose of this study was to investigate the association between hyperuricemia and anemia using data from Korean National Health and Nutrition Examination Survey (KNHANES VII; 2016), which is representative of the Korean population. <h3>Methods:</h3> The present study included 5887 participants aged ≥ 19 years from KNHANES VII. Logistic regression was used to examine the association between anemia and hyperuricemia. Subgroup analysis was performed to confirm whether the association between two conditions varies according to participant characteristics. <h3>Results:</h3> In an adjusted model that corrected for body mass index, smoking, drinking, physical activity, income, and education levels, hyperuricemia was 1.4 times more than that those without anemia (HR 1.41, 95% CI 1.01-1.98). The association of anemia with hyperuricemia was not seen under 65 years of age (HR 2.68, 95% CI 1.60-4.48). In addition, this association was not clear in women, but was significant in men (HR 2.62, 95% CI 1.47-4.70). In the results of subgroup analysis according to comorbidities, the association of anemia with hyperuricemia was significant only in subgroups with chronic kidney disease, diabetes, hypertension, metabolic syndrome, and cardiovascular diseases. There was no association between anemia and hyperuricemia in obese subjects, but hyperuricemia risk was higher in non-obese subjects with anemia compared to those who did not have anemia. <h3>Conclusion:</h3> In a Korean representative sample, the risk of hyperuricemia was higher for anemia. The association of anemia with hyperuricemia was more pronounced in subjects with older age, male population, and other comorbid conditions. <h3>Disclosure of Interests:</h3> None declared